{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T14:18:17Z","timestamp":1784297897168,"version":"3.55.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.urolonc.2024.06.024","type":"journal-article","created":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T21:04:38Z","timestamp":1723669478000},"page":"451.e19-451.e29","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Comprehensive behavioural assessment of TERT in bladder cancer"],"prefix":"10.1016","volume":"42","author":[{"given":"Meryem","family":"El Azzouzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajar","family":"El Ahanidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilias","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Tetou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Ameur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mounia","family":"Bensaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abderrahmane","family":"Al Bouzidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Oukabli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaimae Hafidi","family":"Alaoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boutaina","family":"Addoum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imane","family":"Chaoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laila","family":"Benbacer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed El","family":"Mzibri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Attaleb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.urolonc.2024.06.024_bib0001","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.eururo.2023.03.029","article-title":"Epidemiology of bladder cancer in 2023: a systematic review of risk factors","volume":"84","author":"Jubber","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2024.06.024_bib0002","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2016.06.020","article-title":"Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer","volume":"71","author":"Alfred Witjes","year":"2017","journal-title":"Eur. Urol"},{"key":"10.1016\/j.urolonc.2024.06.024_bib0003","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.eururo.2013.06.003","article-title":"EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013","volume":"64","author":"Babjuk","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2024.06.024_bib0004","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1016\/j.purol.2018.07.283","article-title":"Recommandations fran\u00e7aises du Comit\u00e9 de Canc\u00e9rologie de l'AFU \u2013 Actualisation 2018\u20132020\u202f: tumeurs de la vessie","volume":"28","author":"Roupr\u00eat","year":"2018","journal-title":"Progr\u00e8s en Urologie"},{"key":"10.1016\/j.urolonc.2024.06.024_bib0005","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1016\/S1166-7087(16)30704-7","article-title":"Recommandations en onco-urologie 2016-2018 du CCAFU\u202f: Tumeurs de la vessie","volume":"27","author":"Roupr\u00eat","year":"2016","journal-title":"Progr\u00e8s en Urologie"},{"key":"10.1016\/j.urolonc.2024.06.024_bib0006","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/8205836","article-title":"Molecular biomarkers in bladder cancer: novel potential indicators of prognosis and treatment outcomes","volume":"2016","author":"Nagata","year":"2016","journal-title":"Dis Markers"},{"key":"10.1016\/j.urolonc.2024.06.024_bib0007","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1080\/14737159.2020.1699791","article-title":"Current and emerging bladder cancer biomarkers with an emphasis on urine biomarkers","volume":"20","author":"Lopez-Beltran","year":"2020","journal-title":"Expert Rev Mol Diagn"},{"key":"10.1016\/j.urolonc.2024.06.024_bib0008","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1172\/JCI121303","article-title":"DNA Hypermethylation within TERT promoter upregulates TERT expression in cancer","volume":"129","author":"Lee","year":"2019","journal-title":"J Clin Invest"},{"key":"10.1016\/j.urolonc.2024.06.024_bib0009","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/nature05985","article-title":"The common biology of cancer and ageing","volume":"448","author":"Finkel","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.urolonc.2024.06.024_bib0010","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.biochi.2007.07.025","article-title":"Telomerase redefined: integrated regulation of htr and htert for telomere maintenance and telomerase activity","volume":"90","author":"Cairney","year":"2008","journal-title":"Biochimie"},{"key":"10.1016\/j.urolonc.2024.06.024_bib0011","series-title":"In: Madame curie bioscience database","article-title":"Roles for tert and telomerase in cell differenciation and apopptosis","author":"Mattson","year":"2013"},{"key":"10.1016\/j.urolonc.2024.06.024_bib0012","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41585-018-0001-5","article-title":"Implications of TERT promoter mutations and telomerase activity in urothelial carcinogenesis","volume":"15","author":"G\u00fcnes","year":"2018","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.urolonc.2024.06.024_bib0013","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1038\/ncomms3218","article-title":"High Frequency of Telomerase Reverse-Transcriptase Promoter Somatic Mutations in Hepatocellular Carcinoma and Preneoplastic Lesions","volume":"4","author":"Nault","year":"2013","journal-title":"Nat Commun"},{"key":"10.1016\/j.urolonc.2024.06.024_bib0014","doi-asserted-by":"crossref","first-page":"6172","DOI":"10.1038\/s41388-019-0872-9","article-title":"Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer: old actors and new players","volume":"38","author":"Yuan","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.urolonc.2024.06.024_bib0015","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.eururo.2017.03.010","article-title":"Genetic alterations in the molecular subtypes of bladder cancer: illustration in the cancer genome atlas dataset","volume":"72","author":"Choi","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2024.06.024_bib0016","first-page":"289","article-title":"Subtelomeric demethylation deregulated hTERT expression, telomerase activity, and telomere length in four nasopharyngeal carcinoma cell lines","volume":"29","author":"Zhang","year":"2014","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.urolonc.2024.06.024_bib0017","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.euo.2020.12.002","article-title":"Prognostic value of the WHO1973 and WHO2004\/2016 classification systems for grade in primary ta\/t1 non\u2013muscle-invasive bladder cancer: a multicenter european association of urology non\u2013muscle-invasive bladder cancer guidelines panel study","volume":"4","author":"Van Rhijn","year":"2021","journal-title":"European Urology Oncology"},{"key":"10.1016\/j.urolonc.2024.06.024_bib0018","series-title":"Molecular cloning: a laboratory manual","author":"Sambrook","year":"1989"},{"key":"10.1016\/j.urolonc.2024.06.024_bib0019","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.gene.2012.01.095","article-title":"Regulation of the human catalytic subunit of telomerase (hTERT)","volume":"498","author":"Daniel","year":"2012","journal-title":"Gene"},{"key":"10.1016\/j.urolonc.2024.06.024_bib0020","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/nrc2275","article-title":"Telomerase and cancer therapeutics","volume":"8","author":"Harley","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.urolonc.2024.06.024_bib0021","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1002\/ijc.29526","article-title":"Mutations in TERT promoter and FGFR3 and telomere length in bladder cancer: TERT , FGFR3 , telomere length in bladder cancer","volume":"137","author":"Hosen","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.urolonc.2024.06.024_bib0022","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1101\/gad.269498.115","article-title":"Mutation of the TERT promoter, switch to active chromatin, and monoallelic TERT expression in multiple cancers","volume":"29","author":"Stern","year":"2015","journal-title":"Genes Dev"},{"key":"10.1016\/j.urolonc.2024.06.024_bib0023","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1038\/ncomms3185","article-title":"Frequency of TERT promoter mutations in human cancers","volume":"4","author":"Vinagre","year":"2013","journal-title":"Nat Commun"},{"key":"10.1016\/j.urolonc.2024.06.024_bib0024","doi-asserted-by":"crossref","first-page":"7162","DOI":"10.1158\/0008-5472.CAN-13-2498","article-title":"TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine","volume":"73","author":"Kinde","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2024.06.024_bib0025","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1002\/ijc.31935","article-title":"Combined genetic and epigenetic alterations of the TERT promoter affect clinical and biological behavior of bladder cancer","volume":"144","author":"Le\u00e3o","year":"2019","journal-title":"Int J Cancer"},{"key":"10.1016\/j.urolonc.2024.06.024_bib0026","doi-asserted-by":"crossref","first-page":"67435","DOI":"10.18632\/oncotarget.11883","article-title":"Detection of multiple mutations in urinary exfoliated cells from male bladder cancer patients at diagnosis and during follow-up","volume":"7","author":"Critelli","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.urolonc.2024.06.024_bib0027","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3233\/BLC-170152","article-title":"Toward personalised liquid biopsies for urothelial carcinoma: characterisation of ddPCR and Urinary cfDNA for the detection of the TERT 228\u200aG>A\/T mutation","volume":"4","author":"Russo","year":"2018","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.urolonc.2024.06.024_bib0028","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1146\/annurev-pathol-020712-164030","article-title":"The role of telomere biology in cancer","volume":"8","author":"Xu","year":"2013","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.urolonc.2024.06.024_bib0029","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1158\/1055-9965.EPI-14-0228","article-title":"Shorter leukocyte telomere length is independently associated with poor survival in patients with bladder cancer","volume":"23","author":"Russo","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.urolonc.2024.06.024_bib0030","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1111\/j.1442-2042.2004.00960.x","article-title":"Telomerase activity is correlated with lower grade and lower stage bladder carcinomas","volume":"11","author":"Okumura","year":"2004","journal-title":"Int J Urol"},{"key":"10.1016\/j.urolonc.2024.06.024_bib0031","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/nar\/28.3.669","article-title":"Sp1 cooperates with C-Myc to activate transcription of the human telomerase reverse transcriptase gene (hTERT)","volume":"28","author":"Kyo","year":"2000","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.urolonc.2024.06.024_bib0032","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/ng.3781","article-title":"Systematic analysis of telomere length and somatic alterations in 31 cancer types","volume":"49","author":"Barthel","year":"2017","journal-title":"Nat Genet"},{"key":"10.1016\/j.urolonc.2024.06.024_bib0033","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1126\/science.aao0535","article-title":"Mutations in the promoter of the telomerase gene TERT contribute to tumorigenesis by a two-step mechanism","volume":"357","author":"Chiba","year":"2017","journal-title":"Science"},{"issue":"36","key":"10.1016\/j.urolonc.2024.06.024_bib0034","doi-asserted-by":"crossref","first-page":"57726","DOI":"10.18632\/oncotarget.10639","article-title":"A cancer specific hypermethylation signature of the tert promoter predicts biochemical relapse in prostate cancer: a retrospective cohort study","volume":"7","author":"Castelo-Branco","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.urolonc.2024.06.024_bib0035","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/S1470-2045(13)70110-4","article-title":"Methylation of the TERT promoter and risk stratification of childhood brain tumours: an integrative genomic and molecular study","volume":"14","author":"Castelo-Branco","year":"2013","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2024.06.024_bib0036","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3892\/ijo.2023.5526","article-title":"Role of telomere length in human carcinogenesis (Review)","volume":"63","author":"Tsatsakis","year":"2023","journal-title":"Int J Oncol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143924005362?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143924005362?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T08:33:40Z","timestamp":1731746020000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143924005362"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":36,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S1078143924005362"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.06.024","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comprehensive behavioural assessment of TERT in bladder cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.06.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}